Alexion Pharma (ALXN): Could Be The Last Complement Inhibitor Standing - Leerink

Leerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Alexion Pharmaceuticals (NASDAQ: ALXN) and raised his price target to $211 from $210 on the belief that the company's flagship complement inhibition franchise is likely to remain the dominant, if not only, terminal complement inhibitor on the market.

The analyst's research found that the growing number of manufacturers with competing programs in early stage development face significant technical and market-related challenges to match or surpass Soliris. Given the stage of development, any rival program obtaining approval would enter the market after Alexion’s ALXN1210, and its more convenient dosing schedule will be a significant advantage over most competitors. The analyst views Alexion’s complement franchise as durable and capable of sustaining revenue growth throughout the mid-term as the company expands into other rare diseases.

The $1 increase is due to an update in the company's financials as they flow through the analyst's average of PE, PEG and DCF.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $127.22 yesterday.

You May Also Be Interested In

• Piper Sandler Upgrades BlackLine (BL) to Neutral
• Equity LifeStyle Properties (ELS) PT Lowered to $69 at Evercore ISI
• HSBC Starts Auna SA (AUNA) at Buy, 'Just what the doctor prescribed'